
Themis Medicare Ltd. — Investor Relations & Filings
Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| General Updates | 2026-05-12 | English | |
| Please refer to the attachment. | 2026-05-12 | English | |
| Copy of Newspaper Publication | 2026-04-08 | English | |
| Disclosure under SEBI Takeover Regulations | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | |
| Shareholders meeting | 2026-03-28 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45290538 | General Updates | 2026-05-12 | English | ||
| 45290574 | Please refer to the attachment. | 2026-05-12 | English | ||
| 42176406 | Copy of Newspaper Publication | 2026-04-08 | English | ||
| 42182406 | Disclosure under SEBI Takeover Regulations | 2026-04-08 | English | ||
| 42186178 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | ||
| 42206122 | Shareholders meeting | 2026-03-28 | English | ||
| 42211926 | Disclosure under SEBI Takeover Regulations | 2026-03-27 | English | ||
| 42161957 | General Updates | 2026-03-26 | English | ||
| 42190951 | Trading Window | 2026-03-24 | English | ||
| 42196286 | Trading Window | 2026-03-24 | English | ||
| 42172880 | Copy of Newspaper Publication | 2026-03-11 | English | ||
| 42175133 | Shareholders meeting | 2026-03-10 | English | ||
| 42175154 | General Updates | 2026-03-10 | English | ||
| 42165320 | Copy of Newspaper Publication | 2026-02-26 | English | ||
| 42170289 | General Updates | 2026-02-25 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Themis Medicare Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/59390/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=59390 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=59390 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=59390 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 59390}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Themis Medicare Ltd. (id: 59390)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.